Javanshir Janani, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 5632 Annapolis Rd, Suite 4, Bladensburg, MD 20710 Phone: 301-864-7100 Fax: 301-277-4495 |
News Archive
Studies conducted at the Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital show that the drugs ibrutinib and idelalisib used in the targeted treatment of chronic lymphatic leukaemia can significantly prolong the survival time of high-risk patients.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced the commencement of a Phase 1/2 clinical trial with HTI-501 (rHuCAT-L) in women with moderate to severe edematous fibrosclerotic panniculopathy (also known as cellulite).
The Scripps Research Institute (TSRI) today announced the formation of Scripps Advance, a new drug discovery initiative to translate early-stage biomedical research projects, both internal and external to TSRI, into clinical development candidates.
DaVincian Healthcare, a leading innovator in the mobile health and wellness industry, today announced strategic partnerships with social welfare and global technology companies to help remotely connect healthcare providers with patients in need, particularly those in rural and remote areas of the world.
A study of women with cervical or endometrial cancer who require treatment to the para-aortic (PA) lymph nodes can safely receive extended-field intensity modulated radiation therapy (EF-IMRT) without increased risk of duodenal toxicity, according to a study published in the July-August 2015 issue of Practical Radiation Oncology, the American Society for Radiation Oncology's journal focused on the clinical practice of radiation oncology.
› Verified 1 days ago